Herve Rochat

Title: Herve Rochat: Innovator in Peptide Research

Introduction

Herve Rochat is a notable inventor based in Mimet, France. He has made significant contributions to the field of peptide research, particularly in the development of derivatives that have potential therapeutic applications. With a total of 4 patents, his work focuses on innovative solutions for medical challenges.

Latest Patents

Rochat's latest patents include Maurotoxin, PI1, and HSTX1 derivatives. These derivatives of Maurotoxin (MTX) feature a disrupted native disulfide bridge pattern, which is beneficial for treating pathologies linked to dysfunction and activation of Ca-activated and voltage-gated K-channel subtypes, such as IKCa1 or Kv1.2. In one group of derivatives, specific amino acid residues in maurotoxin are replaced, altering the disulfide bridge pattern to Cys3-Cys24, Cys9-Cys29, Cys13-Cys31, and Cys19-Cys34. Notable substitutions include replacing the Arg residue at position 14 and/or the Lys residue at position 15 with a Gln residue, and substituting the Gly residue at position 33 with an Ala residue. Additionally, the PI1 and HsTx1 derivatives with disrupted native disulfide bridge patterns also show promise in therapeutic applications.

Career Highlights

Throughout his career, Rochat has worked with various companies, including Armel S.A. and Gellpep S.A. His innovative research has positioned him as a key figure in the field of peptide technology, contributing to advancements that may lead to new treatment options for serious health conditions.

Collaborations

Rochat has collaborated with notable professionals in his field, including Kamel Mabrouk and Jurphaas Van Rietschoten. These partnerships have enhanced his research efforts and broadened the impact of his work.

Conclusion

Herve Rochat's contributions to peptide research and his innovative patents highlight his role as a significant inventor in the medical field. His work continues to pave the way for potential advancements in treatment methodologies.